The MarketVue®: Bullous Pemphigoid market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
Dermatologist, U.S.: I’m most optimistic for the biologics. I think there’s enough in the pipeline that something will hopefully get an on-label indication, and that’ll improve accessibility for patients to these treatments. Being able to give somebody something that’s not increasing their risk of infection and death, but rather helping their symptoms without increasing those risks would be nice and seems attainable.
An analyst from the research firm, stated: 'Physicians seem to agree that emerging therapies like FcRn inhibitors hold promise in reducing the circulating autoantibodies that drive autoimmune diseases like bullous pemphigoid. However, BP is also characterized by complement and eosinophil activity, so we’ll have to await clinical trial results to see if these therapies measure up to steroids in terms of efficacy and speed in controlling the inflammation found in the acute phase of the disease.'
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
Topics covered in this report:
- Disease overview: Review the disease pathophysiology and potential druggable targets
- Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
- Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
- Unmet needs: Identify opportunities to address treatment or disease management gaps
- Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
- Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing
Methodology:
Research for the MarketVue®: Bullous Pemphigoid report is supported by 4 qualitative interviews with key opinion leaders, a quantitative survey with 25 U.S. physicians and secondary research.Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom).Key companies mentioned:
- Regeneron
- Sanofi
- AstraZeneca
- argenx
- AKARI Therapeutics
- Immune Pharmaceuticals
Key drugs mentioned:
- Corticosteroids
- Tetracycline
- Rituximab (Rituxan)
- Omalizumab (Xolair)
- Dupilumab (Dupixent)
- Benralizumab (Fasenra)
- Doxycycline
- Dapsone+J17
- Niacinamide
- Minocycline
- Azathioprine
- Cyclophosphamide
- Methotrexate
- Cyclosporine
- IVIg (Panzyga)
- Efgartigimod
- Nomacopan
- Prednisone
- Bertilimumab
- Mycophenolate mofetil
Key takeaways from the report:
Bullous pemphigoid (BP) is a rare, autoimmune, blistering disease for which there are no approved therapies. BP is associated with significant morbidities such as:
- Subepidermal blistering
- Severe pruritis
- Infection
- Diminished quality of life
Dermatologist, U.S.: I’m most optimistic for the biologics. I think there’s enough in the pipeline that something will hopefully get an on-label indication, and that’ll improve accessibility for patients to these treatments. Being able to give somebody something that’s not increasing their risk of infection and death, but rather helping their symptoms without increasing those risks would be nice and seems attainable.
The BP pipeline contains a number of biologics, including:
- argenx’s FcRn inhibitor - efgartigimod
- Regeneron/Sanofi’s IL-4/IL-13 inhibitor - dupilumab
- AstraZeneca’s IL-5 inhibitor - benralizumab
An analyst from the research firm, stated: 'Physicians seem to agree that emerging therapies like FcRn inhibitors hold promise in reducing the circulating autoantibodies that drive autoimmune diseases like bullous pemphigoid. However, BP is also characterized by complement and eosinophil activity, so we’ll have to await clinical trial results to see if these therapies measure up to steroids in terms of efficacy and speed in controlling the inflammation found in the acute phase of the disease.'
Table of Contents
1. DISEASE OVERVIEW- A rare, progressive autoimmune disease causing blistering of the skin and mucous membranes
- Table 1.1. Select diagnostic features of patients presenting with Pemphigus Vulgaris and Pemphigus Foliaceus
- Underlying pathophysiology dictates current and future targets for therapy
- Figure 1.1. The pathophysiology of pemphigus
- Disease definition
- Figure 2.1. Diagnosed prevalent cases of BP by region
- Table 2.1 Diagnosed incident, prevalent, and drug-treated patients in the US and EU5
- Diagnosis overview
- Figure 3.1. Diagnostic pathway for bullous pemphigoid patients
- Once patients reach a physician familiar with bullous pemphigoid, diagnostic testing for auto-antibodies is standard
- Figure 3.2. Dermatologist-reported percentage of bullous pemphigoid patients misdiagnosed/not diagnosed in a timely manner
- Figure 3.3. Percentage of bullous pemphigoid patients in each severity category
- Figure 3.4. Percentage of bullous pemphigoid patients in each age category (years)
- Achieving complete response off long-term corticosteroid treatment is the ultimate goal
- Figure 3.5. Surveyed U.S. dermatologist bullous pemphigoid patient load
- Table 3.2. Treatment goals for bullous pemphigoid
- Figure 3.6. Dermatologist-reported proportion of bullous pemphigoid patients currently treated with drug therapy
- Treatment flow for bullous pemphigoid
- While there is no standard approach to treatment, corticosteroids are the mainstay of treatment
- Figure 3.7. Dermatologist-reported current treatment share for
- bullous pemphigoid
- Figure 3.8. Dermatologist-reported BP patients’ response to treatment
- Bullous pemphigoid has periods of higher activity and remission that wax and wane
- Table 3.3. Key terms to know for bullous pemphigoid
- Figure 3.9. Dermatologist-reported proportion of BP patients achieving different disease responses
- Upsides and downsides of current bullous pemphigoid treatments
- Physician perspectives on current treatment regimens
- Table 3.4. KOL insights on current regimens
- Key treatment dynamics that shape disease management and drug use in bullous pemphigoid
- Figure 3.10. Dermatologist-reported % of BP patients not well-managed by current treatments
- Table 3.5. Must-know bullous pemphigoid treatment dynamics
- Figure 3.11. Dermatologist ranking of attribute importance as an outcome in a pivotal trial
- Key treatment dynamics that shape disease management and drug use in bullous pemphigoid
- Figure 3.12. Dermatologists’ perceptions of aspects of bullous pemphigoid treatment versus pemphigus
- There is large opportunity for corticosteroid-sparing therapies that are just as effective as prednisone
- Figure 3.13. Important dynamics of bullous pemphigoid market evolution
- Overview
- Figure 4.1. Dermatologist-reported unmet needs in bullous pemphigoid
- Physician insights on the most urgent unmet needs for pemphigoid
- Overview
- Figure 5.1. Key differences in efgartigimod trials in pemphigus vulgaris/foliaceus and bullous pemphigoid
- Table 5.1. Comparison of ongoing trials of therapies for bullous pemphigoid
- Physician insights on the pemphigoid pipeline
- Overview
- Table 6.1. Bullous pemphigoid therapy pricing, U.S.
- Figure 6.1. Bullous pemphigoid patients by insurance type
- Table 6.2. Typical U.S. commercial payer coverage of Rituximab for pemphigus patients (United Healthcare, Aetna, BlueCross BlueShield, Cigna)
- Primary market research approach
- Epidemiology methodology
Samples
LOADING...
Companies Mentioned
- Regeneron
- Sanofi
- AstraZeneca
- argenx
- AKARI Therapeutics
- Immune Pharmaceuticals
